Company / SG&A Expense
Imunon, Inc. SG&A Expense History
FY2015-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$13.7M
FY2023
5-year range
$7.6M / $13.7M
FY2019-FY2023
Trend
+25.7%
vs FY2022
Sector context
Sector data unavailable
Latest sector comparison
What the data says
SG&A Expense has fluctuated over the past 7 years, ranging from $6M in FY2018 to $14M in FY2023.
Based on SEC 10-K filings.
$14M in FY2023 with a 5-year CAGR of +18.4%.
Increased from $8M to $14M over the past 2 years.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +19.6%
- 5-Year CAGR
- +18.4%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +18.4%, indicating consistent growth.
- In FY2023, sg&a expense increased 25.7% year-over-year.
- Lowest sg&a expense in the period was in FY2018.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -4.82 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2023 | $13.7M | +25.7% |
| FY2022 | $10.9M | +42.5% |
| FY2021 | $7.6M | -4.5% |
| FY2020 | $8.0M | -17.5% |
| FY2019 | $9.7M | +64.7% |
| FY2018 | $5.9M | -10.0% |
| FY2015 | $6.5M | - |
As of FY2023 · SEC 10-K · Updated Jun 24, 2026